# Neoadjuvant SLOT Versus SOX in Patients With Locally Advanced, Resectable Gastric/Esophagogastric Junction (EGJ) Cancer

> **NCT02512380** · PHASE3 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 380 (estimated)

## Conditions studied

- Gastric Adenocarcinoma

## Interventions

- **DRUG:** Docetaxel;oxaliplatin;s1
- **DRUG:** oxaliplatin;s1

## Key facts

- **NCT ID:** NCT02512380
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-07
- **Primary completion:** 2019-07
- **Final completion:** 2021-07
- **Target enrollment:** 380 (ESTIMATED)
- **Last updated:** 2015-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02512380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02512380, "Neoadjuvant SLOT Versus SOX in Patients With Locally Advanced, Resectable Gastric/Esophagogastric Junction (EGJ) Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02512380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*